202 related articles for article (PubMed ID: 9305902)
21. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
Grompe M; Overturf K; al-Dhalimy M; Finegold M
J Inherit Metab Dis; 1998 Aug; 21(5):518-31. PubMed ID: 9728332
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.
Overturf K; al-Dhalimy M; Ou CN; Finegold M; Tanguay R; Lieber A; Kay M; Grompe M
Hum Gene Ther; 1997 Mar; 8(5):513-21. PubMed ID: 9095403
[TBL] [Abstract][Full Text] [Related]
23. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
[TBL] [Abstract][Full Text] [Related]
25. A nonsense mutation in the 4-hydroxyphenylpyruvic acid dioxygenase gene (Hpd) causes skipping of the constitutive exon and hypertyrosinemia in mouse strain III.
Endo F; Awata H; Katoh H; Matsuda I
Genomics; 1995 Jan; 25(1):164-9. PubMed ID: 7774914
[TBL] [Abstract][Full Text] [Related]
26. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
28. On the enzymic defects in hereditary tyrosinemia.
Lindblad B; Lindstedt S; Steen G
Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
[TBL] [Abstract][Full Text] [Related]
29. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
30. Fungal metabolic model for human type I hereditary tyrosinaemia.
Fernández-Cañón JM; Peñalva MA
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9132-6. PubMed ID: 7568087
[TBL] [Abstract][Full Text] [Related]
31. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
32. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice.
Ruppert S; Kelsey G; Schedl A; Schmid E; Thies E; Schütz G
Genes Dev; 1992 Aug; 6(8):1430-43. PubMed ID: 1644288
[TBL] [Abstract][Full Text] [Related]
33. Metabolic studies in a mouse model of hepatorenal tyrosinemia: absence of perinatal abnormalities.
Collins JC; Buchanan DN; Thoene JG; Erickson RP; Brooks SS; Gluecksohn-Waelsch S
Biochem Biophys Res Commun; 1992 Aug; 187(1):340-6. PubMed ID: 1520318
[TBL] [Abstract][Full Text] [Related]
34. Genetically blocking
Gu P; Yang Q; Chen B; Bie YN; Liu W; Tian Y; Luo H; Xu T; Liang C; Ye X; Liu Y; Tang X; Gu W
Mol Ther Methods Clin Dev; 2021 Jun; 21():530-547. PubMed ID: 33997102
[TBL] [Abstract][Full Text] [Related]
35. An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1.
Gu P; Xie L; Chen T; Yang Q; Zhang X; Liu R; Guo J; Wei R; Li D; Jiang Y; Chen Y; Gong W; Chen P
J Hepatol; 2024 Mar; 80(3):454-466. PubMed ID: 37952766
[TBL] [Abstract][Full Text] [Related]
36. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.
Tomoeda K; Awata H; Matsuura T; Matsuda I; Ploechl E; Milovac T; Boneh A; Scott CR; Danks DM; Endo F
Mol Genet Metab; 2000 Nov; 71(3):506-10. PubMed ID: 11073718
[TBL] [Abstract][Full Text] [Related]
38. Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia.
Berger R; van Faassen H; Smith GP
Clin Chim Acta; 1983 Oct; 134(1-2):129-41. PubMed ID: 6652907
[TBL] [Abstract][Full Text] [Related]
39. Disruption of fumarylacetoacetate hydrolase causes spontaneous cell death under short-day conditions in Arabidopsis.
Han C; Ren C; Zhi T; Zhou Z; Liu Y; Chen F; Peng W; Xie D
Plant Physiol; 2013 Aug; 162(4):1956-64. PubMed ID: 23743712
[TBL] [Abstract][Full Text] [Related]
40. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
